Over 1600 Total Lots Up For Auction at Four Locations - NJ Cleansweep 05/07, NJ Cleansweep 05/08, CA 05/09, CO 05/12

Cecilia Danckwardt-Lillieström

C-RAD appoints new CFO
August 28, 2018
Rad Oncology Radiation Therapy
C-RAD today announces that Cecilia Danckwardt-Lillieström has been appointed Chief Financial Officer effective October 15, 2018, succeeding Therése Björklund who will assume another position within the finance department at the company.

Cecilia has an extensive experience and has held several leading positions within finance. She is currently a Senior Manager & Head of the Uppsala office for the financial audit and consulting firm KPMG, a position she has held for 3 years. Prior to that, she held the position as CFO for Fastum UBC Förvaltning AB. She has also worked for RaySearch Laboratories AB as CFO, as Director of Finance for MySQL AB, for Biotage AB (publ) as Group controller and for PwC as Senior Manager. Cecilia holds a master’s degree in business and Economics from the Uppsala University.

Therése decided to step down from the position as CFO for personal reasons.
stats
DOTmed text ad

We repair MRI Coils, RF amplifiers, Gradient Amplifiers and Injectors.

MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013

stats
“Cecilia´s very broad financial experience will be a great asset for C-RAD supporting the growing organization. I am very much looking forward to work with Cecilia as our CFO and I am confident that she will be a strong addition to the management team of C-RAD.” says Tim Thurn, CEO C-RAD AB

“I am really looking forward to join the management team of C-RAD. I will certainly do my best to contribute in the continuing development of the finance strategy as well as the future growth of C-RAD”, says Cecilia Danckwardt-Lillieström.

“I want to take the opportunity to thank Therése for the excellent work and the support during the past two years. As a member of the management team she has made an important contribution to build up the organization and finance department in a period a significant growth. I very much welcome her decision to stay in the organization after her change.” says Tim Thurn, CEO C-RAD AB.


About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.

You Must Be Logged In To Post A Comment

 

Rad Oncology Homepage

Will you be attending this year's National Proton Conference?
Q&A with Jennifer Maggiore, the National Association for Proton Therapy’s (NAPT) executive director
Varian and Embolx to jointly market embolization microcatheter in US
Expanding interventional oncology portfolio with a focus on liver-directed therapies
FDA clears Novartis’ Pluvicto for earlier use in PSMA-positive prostate cancer
Approved for patients who received one androgen receptor pathway inhibitor (ARPI) but not chemotherapy
World Theranostics Day: The dawn of precision cancer care
Insights from Dr. Ilya Gipp, oncology chief medical officer at GE HealthCare
Eckert & Ziegler to supply lu-177 to AtomVie under new global agreement
Increasingly used in targeted radiopharmaceutical therapies for various cancers
Congress reintroduces ROCR Act to reform Medicare payments for radiation therapy
Seeks to replace per-treatment reimbursement model with episode-based system
More than 16,000 more linear accelerators needed to meet global demand by 2045: study
Researchers highlight urgent need for investment in global radiotherapy infrastructure
RefleXion expands SCINTIX radiotherapy with first freestanding cancer center install
X1 platform provides biology-guided treatment in real time
University Hospitals to build $39 million regional cancer hub at UH TriPoint in Ohio
Follows similar expansions at UH Avon and UH Minoff health centers
The Case FOR radiologic detection & diagnosis versus blood, urine and hormone testing.
ProstatID: A Smarter, Non-Invasive Approach to Prostate Cancer Detection